Nateglinide is an amino acid derivative and an oral antidiabetic drug used to treat patients with type 2 diabetes. The action of nateglinide depends on the function of pancreatic beta cells. Nateglinide binds to the ATP-sensitive K channel receptor on the beta cell membrane and closes it, causing cell depolarization, calcium channel opening, calcium influx, stimulating insulin secretion, and lowering blood sugar. The insulin secretion-promoting effect of nateglinide depends on the glucose level. When the glucose level is low, the insulin secretion is weakened. Nateglinide has a high degree of tissue selectivity and has a low affinity for cardiac muscle and skeletal muscle.

After passing through the blood-cerebrospinal fluid barrier, it is decomposed into glutamate and gamma-aminobutyric acid (GABA). Glutamate is involved in the information transmission of the central nervous system. Gamma-aminobutyric acid can antagonize the excitotoxic effects of glutamate, improve nerve cell metabolism, maintain nerve stress resistance, reduce the effect of blood ammonia, and improve brain function.

After passing through the blood-cerebrospinal fluid barrier, it is decomposed into glutamate and gamma-aminobutyric acid (GABA). Glutamate is involved in the information transmission of the central nervous system. Gamma-aminobutyric acid can antagonize the excitotoxic effects of glutamate, improve nerve cell metabolism, maintain nerve stress resistance, reduce the effect of blood ammonia, and improve brain function.

Meloxicam is a nonsteroidal anti-inflammatory analgesic (NSAID) of the enolic acid class, which has anti-inflammatory, analgesic and antipyretic effects. It exerts the above effects by inhibiting the biosynthesis of inflammatory mediators prostaglandins, and its selective inhibition of COX-2 is stronger than that of COX-1, thereby reducing gastrointestinal and renal side effects. Clinical studies have shown that the incidence of gastrointestinal adverse reactions is low when the recommended dose is used.